• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新发霍奇金和非霍奇金淋巴瘤患者的健康相关生活质量特征:REALYSA 队列纳入的 3922 例患者的真实世界研究。

Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.

机构信息

Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France; Department of Human and Social Sciences, Centre Léon Bérard, Lyon, France; French National Platform Quality of Life and Cancer, Lyon, France.

Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France.

出版信息

Eur J Cancer. 2024 Sep;208:114210. doi: 10.1016/j.ejca.2024.114210. Epub 2024 Jul 4.

DOI:10.1016/j.ejca.2024.114210
PMID:39002346
Abstract

INTRODUCTION

Considering the notable advances made in the treatment of lymphoma, assessment of health-related quality of life (HRQoL) of lymphoma patients has become a critical aspect to consider both in clinical research and routine practice. However, there is paucity of information about lymphoma specific HRQoL profile at diagnosis.

PATIENTS AND METHODS

HRQoL at diagnosis was assessed for 3922 adult patients with newly diagnosed high-grade (HG) (n = 1994), low-grade (LG) (n = 1053) non-Hodgkin (NHL) and Hodgkin (HL) (n = 875) lymphomas included in REal world dAta in LYmphoma and Survival in Adults (REALYSA, NCT03869619), a prospective non-interventional multicentric cohort in France. Disease-specific HRQoL aspects were assessed with three validated EORTC questionnaires, namely, the QLQ-NHL-HG29, the QLQ-NHL-LG20 and the QLQ-HL27, for patients with NHL-HG, NHL-LG and HL, respectively.

RESULTS

We confirmed the high-level of completion of these questionnaires in REALYSA cohort, ranging from 84 % for QLQ-HG29 to 88 % for QLQ-HL27. The proportion of patients with impaired global health status was as follows: T-cell NHL, 67 %; diffuse large B-cell (DLBCL), 62 %; Burkitt, 61 %; HL, 53 %; marginal zone, 49 %; mantle cell, 48 %; follicular, 47 %. Multivariable regression analyses for DLBCL, follicular and HL showed that gender, performance status and B symptoms were independently associated with all HRQoL dimensions. However, a variable effect of age and stage were observed among these three subtypes.

CONCLUSIONS

A comprehensive analysis was made describing the HRQoL profile of newly diagnosed patients with different types of lymphomas. Our data may help to enhance the interpretation of HRQoL results in future studies using the recently validated EORTC lymphoma specific questionnaires.

摘要

简介

考虑到淋巴瘤治疗方面的显著进展,评估淋巴瘤患者的健康相关生活质量(HRQoL)已成为临床研究和常规实践中都需要考虑的关键方面。然而,在诊断时有关淋巴瘤特异性 HRQoL 特征的信息却很少。

患者和方法

REALYSA(NCT03869619)是一项在法国进行的前瞻性、非干预性、多中心队列研究,共纳入了 3922 例新诊断的高级别(HG)(n=1994)、低级别(LG)(n=1053)非霍奇金(NHL)和霍奇金(HL)(n=875)淋巴瘤成年患者,评估了他们在诊断时的 HRQoL。采用三个经过验证的 EORTC 问卷,即 NHL-HG29 问卷、NHL-LG20 问卷和 HL27 问卷,分别评估 NHL-HG、NHL-LG 和 HL 患者的疾病特异性 HRQoL 方面。

结果

我们证实了 REALYSA 队列中这些问卷的高完成率,范围从 QLQ-HG29 的 84%到 QLQ-HL27 的 88%。全球健康状况受损的患者比例如下:T 细胞 NHL,67%;弥漫性大 B 细胞(DLBCL),62%;伯基特,61%;HL,53%;边缘区,49%;套细胞,48%;滤泡性,47%。多变量回归分析显示,对于 DLBCL、滤泡性和 HL,性别、表现状态和 B 症状与所有 HRQoL 维度独立相关。然而,在这三种亚型中,年龄和分期的影响是可变的。

结论

对不同类型淋巴瘤新诊断患者的 HRQoL 特征进行了全面分析。我们的数据可能有助于在未来使用最近验证的 EORTC 淋巴瘤特异性问卷的研究中更好地解释 HRQoL 结果。

相似文献

1
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.新发霍奇金和非霍奇金淋巴瘤患者的健康相关生活质量特征:REALYSA 队列纳入的 3922 例患者的真实世界研究。
Eur J Cancer. 2024 Sep;208:114210. doi: 10.1016/j.ejca.2024.114210. Epub 2024 Jul 4.
2
International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).国际验证用于评估高级别非霍奇金淋巴瘤(QLQ-NHL-HG29)和低级别非霍奇金淋巴瘤(QLQ-NHL-LG20)患者健康相关生活质量的两个 EORTC 问卷。
Cancer. 2023 Sep 1;129(17):2727-2740. doi: 10.1002/cncr.34822. Epub 2023 May 19.
3
International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.EORTC 四种特定于疾病的生活质量问卷在霍奇金淋巴瘤、高低级别非霍奇金淋巴瘤和慢性淋巴细胞白血病患者中的国际发展。
Qual Life Res. 2018 Feb;27(2):333-345. doi: 10.1007/s11136-017-1718-y. Epub 2017 Nov 10.
4
Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study.长期霍奇金淋巴瘤和非霍奇金淋巴瘤幸存者的疲劳水平随时间变化:EORTC-LYSA 联合横断面研究。
Health Qual Life Outcomes. 2019 Jul 2;17(1):115. doi: 10.1186/s12955-019-1186-x.
5
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.一项具有流行病学、临床、生物学和治疗信息的法国多中心前瞻性预后队列研究,旨在提高对淋巴瘤患者的认识:“真实世界淋巴瘤数据和成人生存”(REALYSA)队列研究方案。
BMC Public Health. 2021 Mar 2;21(1):432. doi: 10.1186/s12889-021-10433-4.
6
International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27.霍奇金淋巴瘤健康相关生活质量问卷的国际验证:EORTC QLQ-HL27。
Blood Adv. 2023 Nov 28;7(22):7045-7055. doi: 10.1182/bloodadvances.2023010841.
7
Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors.晚期霍奇金淋巴瘤患者及霍奇金淋巴瘤幸存者中欧洲癌症研究与治疗组织生活质量核心问卷(EORTC QLQ-C30)的参考值。
Eur J Haematol. 2021 May;106(5):697-707. doi: 10.1111/ejh.13601. Epub 2021 Feb 28.
8
Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study.非霍奇金淋巴瘤幸存者的健康相关生活质量:一项前瞻性队列研究。
Cancer Res Treat. 2018 Oct;50(4):1051-1063. doi: 10.4143/crt.2017.207. Epub 2017 Nov 9.
9
Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.弥漫性大 B 细胞淋巴瘤诊断 1 年后幸存者的生活质量:LYSA 研究。
Ann Hematol. 2022 Feb;101(2):317-332. doi: 10.1007/s00277-021-04689-4. Epub 2021 Oct 6.
10
Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France.法国霍奇金淋巴瘤和主要 B 细胞非霍奇金淋巴瘤的真实世界疾病负担。
J Med Econ. 2020 Mar;23(3):235-242. doi: 10.1080/13696998.2019.1702990. Epub 2019 Dec 26.

引用本文的文献

1
Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial.依鲁替尼、来那度胺和利妥昔单抗治疗复发套细胞淋巴瘤:北欧淋巴瘤组MCL6腓利门试验的长期随访
Hemasphere. 2025 Mar 18;9(3):e70101. doi: 10.1002/hem3.70101. eCollection 2025 Mar.